Immuron CEO Steven Lydeamore to Unveil Strategic Vision at Kalkine Media Webinar on July 20, 2026

Immuron’s Proprietary Polyclonal Antibody Platform Technology

Immuron Limited specialises in developing orally delivered targeted polyclonal antibodies to treat infectious diseases. Its proprietary platform is based on polyclonal immunoglobulins (IgG) sourced from engineered hyper-immune bovine colostrum. This innovative technology enables the production of highly specific immunoglobulins targeting enteric pathogens while maintaining oral efficacy, a vital advantage for gastrointestinal infection treatment.

The platform’s strength lies in bovine IgG’s ability to endure the stomach’s acidic environment and resist proteolytic enzymes in the gastrointestinal tract, preserving therapeutic activity. This allows the antibodies to act directly on pathogenic bacteria in the GI tract. Immuron’s technology supports the development of medicines across diverse infectious diseases by blocking viruses or bacteria at mucosal surfaces and neutralising their toxins, forming a broad foundation for its pipeline.

Travelan Market Potential and Regulatory Approvals in Key Regions

Travelan (IMM-124E), Immuron’s lead commercial product, is an orally administered passive immunotherapy designed to prevent travellers' diarrhea, a common digestive disorder caused by pathogenic bacteria and their toxins. Travelan is a purified tabletised preparation of hyperimmune bovine antibodies that bind to diarrhea-causing bacteria when taken with meals, preventing colonisation and disease. It is produced from colostrum of cattle immunised with vaccines containing antigens from multiple human-derived enterotoxigenic E. coli (ETEC) strains.

Travelan has secured regulatory approval and market presence in multiple jurisdictions: in Australia, it is listed on the Australian Register for Therapeutic Goods (AUST L 106709) with indications to reduce travellers' diarrhea risk and minor gastrointestinal disorders; in Canada, it is licensed as a natural health product (NPN 80046016) for travellers' diarrhea risk reduction; in the US, it is marketed as a dietary supplement for digestive protection. Travellers' diarrhea remains a major global health concern, especially for deployed US military personnel, who face high exposure and disease burden.

IMM-124E Antibody Composition and ETEC Targeting Mechanism

Immuron’s clinical and commercial data validate the IMM-124E formulation behind Travelan . The hyperimmune colostrum is derived from cattle immunised with a vaccine containing antigens from 13 ETEC strains, the leading cause of travellers' diarrhea. The colostrum contains high levels of polyclonal antibodies targeting ETEC antigens such as lipopolysaccharide (LPS), colonisation factor antigen I (CFA-I), and Flagellin. These antibodies exhibit stronger binding and neutralising activity compared to those from unvaccinated cattle.

IMM-124E antibodies target both the variable O-polysaccharide and conserved oligosaccharide core 'R' regions of LPS from the 13 serotypes, providing broad coverage against common ETEC strains. This multi-target strategy enhances Travelan ’s effectiveness against diverse diarrhea-causing bacteria encountered globally. IMM-124E is formulated into convenient oral tablets for prophylactic use.

IMM-529 Development for Clostridioides difficile Infection Prevention and Treatment

Immuron is advancing IMM-529 as an adjunct therapy alongside standard antibiotics for preventing and treating recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies specifically target C. difficile to aid infection clearance and promote gut flora restoration, offering a promising oral preventative for recurrent CDI. The company collaborates with Dr. Dena Lyras’ team at Monash University to develop vaccines producing bovine colostrum antibodies targeting three key C. difficile virulence factors.

IMM-529’s triple-target approach addresses Toxin B (TcB), spores, and surface layer proteins of vegetative cells, tackling multiple disease mechanisms. Preclinical models show strong results: 80% prevention of primary disease (P=0.0052), 67% protection against recurrence (P<0.01), and 78.6% treatment efficacy (P<0.0001 for TcB HBC). The antibodies cross-react with various human C. difficile strains, including hypervirulent types, indicating broad clinical potential. IMM-529 is reportedly the only investigational drug demonstrating therapeutic potential across all CDI disease phases.

ProIBS Distribution and Irritable Bowel Syndrome Market Opportunity

Immuron has secured exclusive distribution rights with Calmino group AB for ProIBS in Australia and New Zealand. ProIBS is a certified medical device formulated to alleviate irritable bowel syndrome (IBS) symptoms such as abdominal pain, bloating, and irregular bowel movements. It contains AVH200 , derived from Aloe barbadensis Mill., which supports the intestinal mucosal barrier. Designed for long-term use, ProIBS is safe with no known drug interactions.

The IBS market presents a significant commercial opportunity. IBS affects about 30% of the population, with higher prevalence in females. The Australian "Digestives & Intestinal Remedies" market, encompassing IBS treatments, generated approximately AU$221.14 million in 2025 with expected growth. Clinical data from Calmino shows high user satisfaction: 94% found ProIBS helpful, 91% reported daily life improvement, and 98% would recommend it.

CEO Steven Lydeamore to Discuss Strategic Direction at Kalkine Media Webinar

CEO Steven Lydeamore’s upcoming presentation at the Kalkine Media Webinar on 20 July 2026 at 12:30pm AEST highlights Immuron’s dedication to transparent communication with investors and stakeholders. The virtual event will provide insights into the company’s strategic priorities, pipeline progress, commercial strategies, market opportunities, and capital allocation plans.

The webinar’s public format ensures accessibility for domestic and international investors, reflecting Immuron’s dual ASX and NASDAQ listings. This presentation follows ongoing development and commercial initiatives, offering management a platform to explain the scientific and commercial rationale behind Immuron’s infectious disease therapeutic strategies.

Dual ASX and NASDAQ Listings Enhance Capital Market Access

Immuron Limited is dual-listed on the Australian Securities Exchange (ASX:IMC) and the NASDAQ (IMRN) in the United States. This dual listing expands capital market access, liquidity, and investor reach across Australia and the US. It aligns with the company’s operational footprint and market ambitions spanning these regions and internationally.

The dual exchange presence facilitates engagement with institutional and retail investors globally and increases Immuron’s visibility within the biopharmaceutical investment community. The NASDAQ listing particularly attracts US investors interested in infectious disease therapeutics and digestive health markets.

Sector Trends Driving Infectious Disease Therapeutic Innovation

Immuron’s focus on orally delivered antibodies for infectious diseases addresses critical sector drivers such as rising antibiotic resistance, which demands novel therapeutic alternatives. Its passive immunotherapy platform offers a distinct mechanism for infection prevention and treatment, complementing or substituting traditional antibiotics. Travellers' diarrhea remains a significant global health issue, especially for military personnel with high exposure risk.

Recurrent CDI represents a major unmet medical need due to frequent relapse after standard antibiotic treatment. IMM-529’s adjunctive immunotherapy approach targeting C. difficile virulence factors and promoting gut microbiota restoration addresses this gap. The growing recognition of the gastrointestinal microbiota’s role in health supports the commercial potential of therapies like Immuron’s bovine colostrum-derived polyclonal antibodies.

IMM-529 Development Stage and Regulatory Pathway Outlook

IMM-529 is currently in preclinical and early development stages. Progression to human clinical trials requires successful regulatory approvals, including investigational new drug (IND) applications with agencies such as the US FDA and Australia’s TGA. While preclinical data supports therapeutic potential in prevention, treatment, and relapse of CDI, clinical efficacy must be demonstrated in human studies.

IMM-529’s role as an adjunct to standard antibiotics may streamline clinical trial design and regulatory review by fitting within established CDI treatment frameworks. However, competition from monoclonal antibodies and other immunotherapies in the CDI space presents challenges. Successful commercialisation depends on clinical validation, regulatory clearance, scalable manufacturing, and market access strategies across jurisdictions.